Vanda Pharmaceuticals

Type: Company
Name: Vanda Pharmaceuticals
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Horizon Pharma elects H Thomas Watkins to board

Pharmaceutical company Horizon Pharma (NasdaqGS:HZNP) revealed on Thursday the addition of H Thomas Watkins to its board of directors. In conjunction, Jean-Francois Formela MD has stepped down from its board of directors. Most recently, Watkins was the ... [Published Individual.com - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Vanda announces availability of non-24-hour sleep-wake disorder drug

Vanda Pharmaceuticals Inc., a biopharmaceutical company, has announced the availability of HETLIOZ, an FDA-approved treatment for non-24-hour sleep-wake disorder, or Non-24. Vanda has launched HETLIOZSolutions to support and facilitate the treatment of ... [Published Individual.com - Apr 18 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Vanda Pharma introduces Hetlioz in US market to treat non-24-hour sleep-wake disorder

Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company focused on the development and commercialization of products for the treatment of CNS disorders, has introduced Hetlioz (tasimelteon), the first treatment approved by the US Food and Drug ... [Published PharmaBiz - Apr 11 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 1 reports

VANDA PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form 8-K)

(4-traders.com) Item 8.01. OTHER EVENTS.On April 9, 2014, Vanda Pharmaceuticals Inc. issued a press release announcing,among other things, that HETLIOZ™ has become available for shipment topharmacies in the United States. A copy of the press release is ... [Published 4 Traders - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 85 reports

Biotech Stocks Technical Data -- Research on Cell Therapeutics, Vanda Pharma, Celldex Therapeutics, and Synta Pharma

SOURCE Investor-EdgeEditor Note: For more information about this release, please scroll to bottom.LONDONOn Wednesday, April 09, 2014©2012 PR Newswire. All Rights Reserved. ... [Published KOAM TV - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 2 reports

Vanda makes Hetlioz available in US to treat non-24-hour sleep-wake disorder

Biopharmaceutical firm Vanda Pharmaceuticals has introduced Hetlioz (tasimelteon) in the US for the treatment of patients with Non-24-Hour Sleep-Wake Disorder ... ... [Published Big News Network - Apr 10 2014]
First reported Apr 10 2014 - Updated Apr 10 2014 - 3 reports

Vanda Pharmaceuticals Announces Availability of HETLIOZ™ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)

Vanda Pharmaceuticals Inc. today announced the availability of HETLIOZ™. HETLIOZ™ is the first treatment approved by the U. S Food and Drug Administration for Non-24-Hour Sleep-Wake Disorder, a serious chronic circadian rhythm disorder that affects up ... [Published Insurance News Net - Apr 10 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

Vanda Pharmaceuticals Shares Up 22.5% Since SmarTrend's Buy Recommendation (VNDA)

SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 22.53% as of today's recent price of $15.31. ... [Published Individual.com - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

HETLIOZ (Tasimelteon) Capsule [Vanda Pharmaceuticals Inc.]

First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Vanda Pharmaceuticals Has Returned 33.8% Since SmarTrend Recommendation (VNDA)

SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 33.81% as of today's recent price of $16.72. ... [Published Individual.com - Apr 01 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Vanda Pharmaceuticals Expanding at 2200 Pennsylvania Avenue, N.W.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has amended its lease with landlord Square 54 Office Owner LLC for its headquarters location at 2200 Pennsylvania Avenue, N.W. in Washington, DC. Vanda Pharmaceuticals Inc. originally signed a lease for 21,400 ... [Published Citybizlist - Mar 25 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

41.7% Return Seen to Date on SmarTrend Vanda Pharmaceuticals Call (VNDA)

SmarTrend identified an Uptrend for Vanda Pharmaceuticals (NASDAQ:VNDA) on December 30th, 2013 at $12.50. In approximately 3 months, Vanda Pharmaceuticals has returned 41.74% as of today's recent price of $17.71. ... [Published Individual.com - Mar 25 2014]

Quotes

"The availability of HETLIOZ marks a major milestone for totally blind people who have been without an approved, safe and effective treatment for Non-24. We are also excited to bring a broad range of services to patients through HETLIOZSolutions" said Mihael H Polymeropoulos, M D , Vanda's President and CEO
...our board as a highly regarded biotechnology leader," said Timothy P Walbert, chairman president and chiefchief executive officer, Horizon Pharma.  "As we continue to grow our commercial business and build our organization through in-licensing and acquisitions, his strategic insights and pharmaceutical leadership experience will be important at this critical juncture for Horizon. Also, I would like to thank Jean-François for his years of service and counsel as a member of our board. Jean-François joined the Horizon board in 2010 in connection with our acquisition of Nitec and has been a valuable member of the board in helping us develop and implement the strategic direction of the Company."
...Doug Braun, USANA Chief Marketing Officer, stated, "The incredible results achieved from last year's challenge were more than we ever anticipated. We were excited to once again help thousands of individuals get healthy, maintain their health, and lose weight this year." The full analyst notes on USANA Health Sciences Inc. are available to download free of charge at:

More Content

All (228) | News (211) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Stock Investors Bid Up Shares of Vanda Pharmace... [Published Individual.com - Apr 21 2014]
Horizon Pharma elects H Thomas Watkins to board [Published Individual.com - Apr 18 2014]
Vanda announces availability of non-24-hour sle... [Published Individual.com - Apr 18 2014]
HORIZON PHARMA : Announces the Appointment of H... [Published 4 Traders - Apr 17 2014]
Momenta Pharmaceuticals is Among the Companies ... [Published Comtex SmarTrend - Apr 16 2014]
Healthcare Companies Report Product Availabilit... [Published Finwin - Apr 14 2014]
Healthcare Companies Report Product Availabilit... [Published ADVFN India - Apr 14 2014]
3 Pharma Mutual Funds Beating the S&P 500 [Published Zacks.com - Apr 11 2014]
Vanda Pharma introduces Hetlioz in US market to... [Published PharmaBiz - Apr 11 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published KOAM TV - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WNEM - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WFLX Fox 29 - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WKRN - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published KWQC - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published KPTV.com - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published State Journal - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published Fox54 - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WSMV - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published Kait 8 - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published ABC 3340 - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published KSWT13 - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WVNS - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published KCTV 5 - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WRIC TV - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WTOC TV - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WSFX-TV - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published NBC12 Online - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WLOX - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published WMBF - Apr 10 2014]
Biotech Stocks Technical Data -- Research on Ce... [Published KPHO Phoenix - Apr 10 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Vanda makes Hetlioz available in US to treat no... [Published PBR - News - Apr 10 2014]
Biopharmaceutical firm Vanda Pharmaceuticals has introduced Hetlioz (tasimelteon) in the US for the treatment of patients with Non-24-Hour Sleep-Wake Disorder (Non-24). ...
Vanda Pharmaceuticals Announces Availability of... [Published PR Newswire: General Business - Apr 10 2014]
WASHINGTON, April 9, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced the availability of HETLIOZ™.  HETLIOZ™ is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake ...
HETLIOZ (Tasimelteon) Capsule [Vanda Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Apr 04 2014]
Updated Date: Apr 4, 2014 EST ...
Blind Adventurer, Erik Weihenmayer, Launches Na... [Published PR Newswire: Health - Feb 28 2014]
WASHINGTON, Feb. 28, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 ...
The Balancing Act® Airing on Lifetime TV Focuse... [Published PR.com Press Releases - Feb 21 2014]
Pompano Beach, FL, February 21, 2014 --( PR.com )-- Popular morning show The Balancing Act® airing on Lifetime® TV focuses on hope and support for the RARE Disease community, caregivers and the little known Non-24-Hour Sleep-Wake Disorder, which affects ...
1 2 3

Press Releases

sort by: Date | Relevance
Biotech Stocks Technical Data -- Research on Ce... [Published Financial Services - Apr 10 2014]
Breakfast Round-up - 52-Weeks High Reset: NextE... [Published Financial Services - Mar 18 2014]
Vanda Pharmaceuticals Reports Third Quarter 201... [Published Financial Services - Nov 07 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.